Plasma Copeptin and the Risk of Diabetes Mellitus
Open accessAbstract
BACKGROUND: Animal studies suggest that the arginine vasopressin system may play a role in glucose metabolism, but data from humans are limited. METHODS AND RESULTS: We analyzed plasma copeptin (copeptin), a stable C-terminal fragment of the arginine vasopressin prohormone. Using baseline and longitudinal data from a Swedish population-based sample (n=4742; mean age, 58 years; 60% women) and multivariable logistic regression, we examined the association of increasing quartiles of copeptin (lowest quartile as reference) with prevalent diabetes mellitus at baseline, insulin resistance (top quartile of fasting plasma insulin among nondiabetic subjects), and incident diabetes mellitus on long-term follow-up. New-onset diabetes mellitus was ascertained through 3 national and regional registers. All models were adjusted for clinical and anthropometric risk factors, cystatin C, and C-reactive protein. In cross-sectional analyses, increasing copeptin was associated with prevalent diabetes mellitus (P=0.04) and insulin resistance (P<0.001). During 12.6 years of follow-up, 174 subjects (4%) developed new-onset diabetes mellitus. The odds of developing diabetes mellitus increased across increasing quartiles of copeptin, even after additional adjustment for baseline fasting glucose and insulin (adjusted odds ratios, 1.0, 1.37, 1.79, and 2.09; P for trend=0.004). The association with incident diabetes mellitus remained significant in analyses restricted to subjects with fasting whole blood glucose <5.4 mmol/L at baseline (adjusted odds ratios, 1.0, 1.80, 1.92, and 3.48; P=0.001). CONCLUSIONS: Elevated copeptin predicts increased risk for diabetes mellitus independently of established clinical risk factors, including fasting glucose and insulin. These findings could have implications for risk assessment, novel antidiabetic treatments, and metabolic side effects from arginine vasopressin system modulation.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
4 of 15 cited sources checked · 3 supported · 0 flagged · accuracy not yet measured
- Premisecitation
Pharmacological blockade of V2R was associated with a 5% incidence of hyperglycemic events during 30 days of tolvaptan treatment in patients with hyponatremia compared to 1% in controls (12/223 vs 2/220).
“pharmacological blockade of the V2R, a potent stimulus of increased AVP secretion,35 was associated with a 5% incidence in hyperglycemic events during 30 days of tolvaptan treatment in patients with hyponatremia compared to 1% in controls, although numbers were small (12/223 vs 2/220).8”
Quote in the paperSubstantial claim1 of 2 sources checked - Study design and conductcitation
Given strict HbA1c criteria for new-onset diabetes in the MHR and the requirement of physician diagnosis in NDR and Diabetes 2000, those classified as new-onset diabetes cases are unlikely to be misclassified.
“On the other hand, given the strict HbA1c criteria for new-onset diabetes in the MHR and the fact that the NDR and Diabetes 2000 registers require a physician diagnosis according to established diagnostic criteria,28, 29 those classified as new-onset diabetes cases in our study are unlikely to be misclassified.”
Quote in the paperSubstantial claim1 of 2 sources checked- cites [28] source
The Research Design and Methods section says NDR data are reported by trained physicians and nurses during clinical visits and gives this study’s definition of type 2 diabetes. It does not say that NDR registration requires a physician diagnosis according to established diagnostic criteria. The MHR criteria and the citing authors’ inference about misclassification are not claims this citation specifically supports. (LLM, conf=0.82)
Experimental — accuracy not yet measured - cites [29] source
- Findingown data
Continuous baseline copeptin was significantly higher in subjects who subsequently developed new-onset diabetes compared with those who did not, regardless of whether subjects with IFG at baseline were included.
“Continuous copeptin concentration at baseline was significantly higher in subjects who subsequently developed new-onset diabetes compared with those who did not, regardless of whether subjects with IFG at baseline were included (Table 3).”
Quote in the paperSubstantial claim - Findingown data
The odds of insulin resistance increased with increasing copeptin in crude and adjusted analyses.
“The odds of insulin resistance increased with increasing copeptin in both crude analysis and after adjustment for model 1 covariates and FBG (Table 2).”
Quote in the paperSubstantial claim - Findingown data
The association between copeptin and incident diabetes remained significant in subjects with baseline fasting whole blood glucose <5.4 mmol/L (adjusted ORs 1.0, 1.80, 1.92, and 3.48; P=0.001).
“The association with incident diabetes remained significant in analyses restricted to subjects with fasting whole blood glucose <5.4 mmol/L at baseline (adjusted odds ratios 1.0, 1.80, 1.92, and 3.48; P=0.001).”
Quote in the paperSubstantial claim
- Findingown data
In subjects free of diabetes, adding copeptin to the clinical model increased the area under the ROC curve from 0.832 to 0.841 (P=0.007).
“and from 0.832 to 0.841 (P=0.007) when copeptin was added to the clinical model of diabetes prediction.”
Quote in the paperSubstantial claim - Findingown data
In cross-sectional analyses, increasing copeptin was associated with insulin resistance (P<0.001).
“In cross-sectional analyses, increasing copeptin was associated with prevalent diabetes (P=0.04) and insulin resistance (P<0.001).”
- Also stated in: § RESULTS · plain
“The odds of insulin resistance increased with increasing copeptin in both crude analysis and after adjustment for model 1 covariates and FBG (Table 2).”
Quote in the paperNot a substantial claim - Also stated in: § RESULTS · plain
- Findingown data
In subjects free of diabetes, adding copeptin to the personal model increased the area under the ROC curve from 0.694 to 0.710 (P=0.08).
“In subjects free of diabetes at baseline, the area under the ROC curve increased from 0.694 to 0.710 (P=0.08) when copeptin was added to the personal model”
Quote in the paperSubstantial claim - Findingown data
After accounting for FBG and all other available diabetes risk factors, individuals in the top quartile of copeptin had a two- to three-fold excess risk of developing diabetes compared with those in the lowest quartile.
“Nonetheless, after accounting for FBG and all other available diabetes risk factors, individuals in the top quartile of copeptin had a two- to three-fold excess risk of developing diabetes compared with those in the lowest quartile of copeptin.”
Quote in the paperSubstantial claim - Findingown data
C-statistics from Cox regression increased with addition of copeptin in subjects without diabetes from 0.702 to 0.718 in the personal model and from 0.835 to 0.844 in the clinical model.
“With addition of copeptin, the C-statistic from Cox regression models increased in subjects without diabetes at baseline from 0.702 to 0.718 in the personal model and from 0.835 to 0.844 in the clinical model.”
Quote in the paperSubstantial claim - Findingown data
At baseline, copeptin concentrations were higher among individuals with diabetes than among those without diabetes.
“At the baseline examination, concentrations of copeptin were higher among individuals with diabetes compared with subjects without diabetes (Table 1).”
Quote in the paperNot a substantial claim - Findingown data
The odds of developing diabetes increased across increasing quartiles of copeptin after additional adjustment for baseline fasting glucose and insulin (adjusted ORs 1.0, 1.37, 1.79, and 2.09; P for trend=0.004).
“The odds of developing diabetes increased across increasing quartiles of copeptin, even after additional adjustment for baseline fasting glucose and insulin (adjusted odds ratios 1.0, 1.37, 1.79, and 2.09; P for trend =0.004).”
Quote in the paperSubstantial claim - Findingreasoning
The improvement in the area under the ROC curve was smaller when the entire sample, including those with IFG, was considered.
“The improvement in the area under the ROC curve was smaller when the entire sample, including those with IFG, was considered.”
Quote in the paperSubstantial claim - Findingown data
During 12.6 years of follow-up, 174 subjects (4%) developed new-onset diabetes.
“During 12.6 years of follow up 174 subjects (4%) developed new-onset diabetes.”
- Also stated in: § RESULTS · plain
“Among participants free of diabetes at baseline (n=4377), 174 subjects developed new-onset diabetes (Table 3) according to the three different registers.”
Quote in the paperNot a substantial claim - Also stated in: § RESULTS · plain
- Findingown data
In cross-sectional analyses, increasing copeptin was associated with prevalent diabetes (P=0.04).
“In cross-sectional analyses, increasing copeptin was associated with prevalent diabetes (P=0.04) and insulin resistance (P<0.001).”
Quote in the paperNot a substantial claim - Premisecitation
In healthy subjects, AVP infusion leads to increased blood glucose levels.
“in healthy subjects AVP infusion leads to increased blood glucose levels.19”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [19] source
- Study design and conductown data
Cox regression models showed unchanged results, excluding potential bias from inter-individual differences in follow-up time in the logistic models.
“Finally, Cox regression models were performed in order to exclude potential bias related to inter-individual differences in follow-up time in the logistic regressions models and the results were unchanged (Supplemental Table 1).”
Quote in the paperNot a substantial claim - Interpretationreasoning
The smaller improvement may result from FBG being a more powerful predictor of diabetes at FBG levels near the diagnostic limit of 6.1 mmol/L.
“This finding may result from FBG being a more powerful predictor of diabetes at FBG levels near the diagnostic limit of 6.1mmol/L.”
Quote in the paperNot a substantial claim - Premisecitation
In patients with poorly controlled diabetes, plasma AVP is markedly elevated.
“In patients with poorly controlled diabetes mellitus, plasma AVP is markedly elevated18”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [18] source
- Interpretationown data
Elevated copeptin predicts increased risk for diabetes, independent of established clinical risk factors, including fasting glucose and insulin.
“Elevated copeptin predicts increased risk for diabetes, independent of established clinical risk factors, including fasting glucose and insulin.”
- Also stated in: § DISCUSSION · plain
“The key finding of our study is that copeptin predicts diabetes development independently of renal function and a broad range of diabetes risk factors at baseline, including FBG and fasting insulin.”
- Also stated in: § DISCUSSION · plain
“In conclusion, copeptin predicts diabetes independently of a broad range of established diabetes risk factors, including fasting levels of glucose and insulin.”
Quote in the paperSubstantial claim - Also stated in: § DISCUSSION · plain
- Premisecitation
Prior human and animal research has indicated that the arginine vasopressin system participates in glucose homeostasis, insulin resistance, and diabetes.
“Previous studies in humans and animals have suggested a role for the AVP system in glucose homeostasis, insulin resistance and diabetes mellitus.”
- Also stated in: § Background · hedged
“Animal studies suggest that the arginine vasopressin (AVP) system may play a role in glucose metabolism, but data from humans are limited.”
Quote in the paperSubstantial claim - Also stated in: § Background · hedged
- Interpretationown data
Our data support a role for the AVP system in the pathophysiology of diabetes.
“Apart from any implications for diabetes prediction, our data support a role for the AVP system in the pathophysiology of diabetes.”
Quote in the paperSubstantial claim - Interpretationown data
Markers not part of the diagnostic criteria for diabetes, such as copeptin, may better signal diabetes susceptibility earlier in the pre-diabetes state.
“Markers that are not part of the diagnostic criteria for diabetes, such as copeptin, may better signal diabetes susceptibility earlier in the pre-diabetes state.”
Quote in the paperSubstantial claim - Premisecitation
The diabetes incidence in our study was comparable with that in a previous Swedish study.
“The diabetes incidence in our study may appear low but was comparable with that in a previous Swedish study.36”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [36] source
- Study design and conductown data
The validity of the register-based new-onset diabetes diagnosis is supported by most well-known risk factors for diabetes being markedly elevated at baseline in subjects who developed diabetes compared with those who did not.
“The validity of the register based new-onset diabetes diagnosis is further supported by most of the well-known risk factors for diabetes being markedly elevated at the MDC-CC baseline in these subjects as compared to those who did not develop diabetes according to the three registers (Table 3).”
Quote in the paperSubstantial claim - Study design and conductown data
The ability to reproduce the association between copeptin and the register-based diabetes endpoint using a FBG-based endpoint in a subset strongly supports the validity of the findings.
“The fact that we were able to reproduce the association between copeptin and the register-based diabetes endpoint, using a FBG-based endpoint in a subset of MDC-CC, strongly supports the validity of our findings.”
Quote in the paperSubstantial claim - Interpretationreasoning
The factors that could lower the observed diabetes incidence would be expected to bias the results towards the null.
“These factors would be expected to bias our results towards the null.”
Quote in the paperNot a substantial claim - Interpretationcitation
Existing therapies that selectively antagonize AVP receptors could have metabolic side effects.
“In addition, our results highlight the possibility that existing therapies that selectively antagonize AVP receptors could have metabolic side effects.”
Quote in the paperSubstantial claim - Interpretationown data
Copeptin could provide incremental information for prediction of diabetes.
“Thus, our findings suggest that copeptin could provide incremental information for prediction of diabetes.”
Quote in the paperSubstantial claim
- Classified as probably not a substantial claim. 3
- May combine two claims. 15
Probably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationRecent findings show a cross-sectional association between plasma vasopressin and insulin resistance.
“Interestingly, recent findings also indicate a cross-sectional association between plasma vasopressin and insulin resistance.3”
Quote in the paperNot a substantial claim1 of 1 sources checked- cites [3] source
May combine two claims.
PremisecitationMice lacking the V1bR have lower fasting plasma glucose and increased insulin sensitivity.
“mice who lack the V1bR have the opposite phenotype of lower fasting plasma glucose and increased insulin sensitivity.21”
Quote in the paperSubstantial claim1 of 1 sources checked- cites [21] source
May combine two claims.
Findingown dataIn subjects without IFG, adding copeptin to classical diabetes risk factors significantly improved the area under the ROC curve, consistent with improved discrimination.
“In subjects without IFG, there was a significant improvement in the area under the ROC curve when copeptin was added to classical diabetes risk factors, consistent with an improvement in discrimination.”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataIn subjects free of diabetes, copeptin was positively associated with fasting blood glucose and plasma insulin.
“In the segment of the population free of diabetes, i.e. in subjects with a range of glucose values that should not affect copeptin through osmolality, copeptin was positively associated with FBG (Figure 1). Additionally, copeptin was positively associated with plasma concentration of insulin (Figure 1).”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataIDI was significantly improved by adding copeptin to the personal model in non-diabetic subjects (P=0.01) and non-IFG subjects (P=0.02), but not when added to the clinical model (P=0.35 and P=0.09).
“IDI was significantly improved by adding copeptin to the personal model for diabetes prediction in both non-diabetic subjects (P=0.01) and in non-IFG subjects (P=0.02) but non-significant when added to the clinical model (P=0.35 in non-diabetic individuals, P=0.09 in non-IFG individuals).”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataIn subjects free of IFG, adding copeptin increased the area under the ROC curve from 0.663 to 0.713 (P=0.03) for the personal model and from 0.783 to 0.805 (P=0.04) for the clinical model.
“In subjects free of IFG at baseline, the area under the ROC curve increased from 0.663 to 0.713 (P=0.03) and from 0.783 to 0.805 (P=0.04) when copeptin was added to the personal model and clinical model for diabetes prediction, respectively.”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataWhen restricted to subjects without IFG, the Cox C-statistic increased from 0.671 to 0.721 in the personal model and from 0.790 to 0.811 in the clinical model.
“When analyses were restricted to subjects without IFG at baseline, the C-statistic increased from 0.671 to 0.721 in the personal model and from 0.790 to 0.811 in the clinical model.”
Quote in the paperNot a substantial claimMay combine two claims.
Findingown dataAmong non-diabetic subjects, copeptin was positively correlated with BMI, insulin, and glucose (Pearson r=0.091, 0.12, and 0.10, respectively; P<0.001 for all).
“Among non-diabetic subjects at baseline, the Pearson correlation between copeptin and potential confounders, i.e. BMI, insulin and glucose, was 0.091, 0.12 and 0.10, respectively (P<0.001 for all).”
Quote in the paperNot a substantial claimMay combine two claims.
Findingown dataFBG was the strongest risk factor for new-onset diabetes; each 1 mmol/L increase in baseline FBG increased the risk of future diabetes with an OR of 11.4 (95% CI 7.4-17.5) in the fully adjusted model.
“As expected, FBG was the strongest risk factor for new-onset diabetes. Each 1 mmol/L increase of FBG at baseline increased the risk of future diabetes with an OR of 11.4 (95% CI 7.4–17.5) in the fully-adjusted model.”
Quote in the paperNot a substantial claimMay combine two claims.
Findingown dataIn a reinvestigated subset, increasing copeptin quartile was associated with new-onset diabetes defined by elevated FBG in subjects free of diabetes (OR=1.42, 95% CI 1.04-1.94; P=0.029) and in subjects free of IFG (OR=1.67, 95% CI 1.07-2.63; P=0.025) after full adjustment.
“Increasing quartile of copeptin was associated with new-onset diabetes using this criterion both in subjects free of diabetes at baseline (OR=1.42 95% CI=1.04–1.94; P=0.029) and in subjects free of IFG at baseline (OR=1.67 95% CI=1.07–2.63; P=0.025) after full adjustment”
Quote in the paperSubstantial claimMay combine two claims.
PremisecitationMice lacking the V1aR display impaired glucose tolerance, insulin resistance, and elevated AVP levels.
“Mice lacking the V1aR display impaired glucose tolerance, insulin resistance and elevated AVP levels20”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [20] source
May combine two claims.
PremisecitationCopeptin is a stable cleavage product of the C-terminal part of the AVP precursor, produced in equimolar amounts with AVP, with a long half-life, and not bound to platelets.
“Copeptin is a cleavage product of the C-terminal part of the AVP precursor that is produced in equimolar amounts with AVP, a process similar to the generation of insulin and C-peptide. In contrast to AVP, copeptin is stable, has a long half-life, and is not bound to platelets.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [22] source
- Rests on an assumption: Plasma AVP measurements are unreliable because AVP is unstable in vivo and ex vivo, is rapidly cleared from plasma, and is largely bound to platelets.
May combine two claims.
InterpretationcitationImpaired V1aR signalling leads to elevated AVP, which then stimulates V1bR and contributes to insulin resistance and diabetes development.
“These findings suggest a model in which impaired signalling through the V1aR leads to elevated levels of AVP which in turn stimulates the V1bR and contributes to insulin resistance and diabetes development.”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
PremisecitationPlasma copeptin reflects vasopressin levels and is elevated in myocardial infarction and predicts prognosis in patients who develop heart failure after myocardial infarction.
“Plasma copeptin, a marker of vasopressin level, is elevated in myocardial infarction1 and predict prognosis in patients who developed heart failure after myocardial infarction.2”
Quote in the paperNot a substantial claim0 of 2 sources checkedProbably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
PremisecitationAVP action is linked to liver glycogenolysis through V1aR and to insulin and glucagon secretion through V1bR.
“In addition, AVP action has been linked to liver glycogenolysis (V1aR) and insulin and glucagon secretion (V1bR).14, 15”
Quote in the paperNot a substantial claim0 of 2 sources checkedMay combine two claims.
Study design and conductown dataThe differences in risk factors were equally or more pronounced when restricted to subjects free of IFG at baseline, excluding the possibility that findings were solely driven by subjects with IFG at baseline.
“Importantly, these differences were equally, or more, pronounced when the study population was restricted to subjects free from IFG at baseline, excluding the possibility that our findings regarding established diabetes risk factors and copeptin in relation to new-onset diabetes were solely driven by subjects who had IFG at the MDC-CC baseline exam.”
Quote in the paperSubstantial claim
The paper relies on this without support.
Plasma AVP measurements are unreliable because AVP is unstable in vivo and ex vivo, is rapidly cleared from plasma, and is largely bound to platelets.
“There are major concerns regarding the reliability of AVP measurements in plasma, as AVP is an unstable molecule both in vivo and ex vivo, is rapidly cleared from plasma and is largely attached to platelets in the circulation.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Large population studies report that high copeptin levels might predict the development of T2D.
“Large population studies report that high copeptin levels might predict the development of T2D (11).”
From Effect of liraglutide on atrial natriuretic peptide, adrenomedullin, and copeptin in PCOS (2018) · cites this paper as [11]
Copeptin shows potential as a rule-out marker in combination with troponin in myocardial infarction, and increased copeptin levels in heart failure are associated with worsened outcome.
“Copeptin shows potential as a rule-out marker in combination with troponin in myocardial infarction, and increased copeptin levels in heart failure are associated with worsened outcome (11).”
From Effect of liraglutide on atrial natriuretic peptide, adrenomedullin, and copeptin in PCOS (2018) · cites this paper as [11]
High plasma copeptin predicts future diabetes mellitus independently of known risk factors.
“High plasma copeptin predicted future diabetes mellitus independently of known risk factors [18].”
From Vasopressin and hydration play a major role in the development of glucose intolerance and hepatic steatosis in obese rats (2015) · cites this paper as [18]
Plasma copeptin, a surrogate for vasopressin, is an independent risk factor for diabetes.
“Recent findings reveal an independent association between plasma copeptin, a surrogate for vasopressin, and risk of diabetes.”
From Low Water Intake and Risk for New-Onset Hyperglycemia (2011) · cites this paper as [1]
The data support the idea that vasopressin, besides its role in urine concentration, is an important actor in glucose homeostasis.
“Our data support the novel idea that vasopressin, besides its role in urine concentration, is also an important actor in glucose homeostasis (1).”
From Low Water Intake and Risk for New-Onset Hyperglycemia (2011) · cites this paper as [1]
Cites
Pencina, M. J., D' Agostino, R. B., D' Agostino, R. B., & Vasan, R. S. (2008) · Statistics in Medicine · doi:10.1002/sim.2929 · Cited by 6,493 · see citing works
Comment on the provisional report from the WHO consultation
(1999) · Diabetic Medicine · doi:10.1046/j.1464-5491.1999.00059.x · Cited by 1,820 · see citing works
Pencina, M. J., & D’Agostino, R. B. (2004) · Statistics in Medicine · doi:10.1002/sim.1802 · Cited by 1,446 · see citing works
Onset of NIDDM occurs at Least 4–7 yr Before Clinical Diagnosis
Harris, M. I., Klein, R., Welborn, T. A., & Knuiman, M. W. (1992) · Diabetes Care · doi:10.2337/diacare.15.7.815 · Cited by 1,306 · see citing works
Tolvaptan, a Selective Oral Vasopressin V <sub>2</sub> -Receptor Antagonist, for Hyponatremia
Schrier, R. W., Gross, P., Gheorghiade, M., Berl, T., Verbalis, J. G., Czerwiec, F. S., & Orlandi, C. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa065181 · Cited by 1,215 · see citing works
Berglund, G., Elmståhl, S., Janzon, L., & LARSSON, S. A. (1993) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1993.tb00647.x · Cited by 640 · see citing works
Self-citationManjer, J., Carlsson, S., Elmståhl, S., Gullberg, B., Janzon, L., Lindström, M., Mattisson, I., & Berglund, G. (2001) · European Journal of Cancer Prevention · doi:10.1097/00008469-200112000-00003 · Cited by 543 · see citing works
Self-citationLolait, S. J., O'Carroll, A.-M., McBride, O. W., Konig, M., Morel, A., & Brownstein, M. J. (1992) · Nature · doi:10.1038/357336a0 · Cited by 524 · see citing works
Arginine Vasopressin in Advanced Vasodilatory Shock
Dünser, M. W., Mayr, A. J., Ulmer, H., Knotzer, H., Sumann, G., Pajk, W., Friesenecker, B. E., & Hasibeder, W. R. (2003) · Circulation · doi:10.1161/01.cir.0000066692.71008.bb · Cited by 523 · see citing works
Molecular cloning and expression of a rat Via arginine vasopressin receptor
Morel, A., O'Carroll, A.-M., Brownstein, M. J., & Lolaft, S. J. (1992) · Nature · doi:10.1038/356523a0 · Cited by 477 · see citing works
Incremental Value of Copeptin for Rapid Rule Out of Acute Myocardial Infarction
Reichlin, T., Hochholzer, W., Stelzig, C., Laule, K., Freidank, H., Morgenthaler, N. G., Bergmann, A., Potocki, M., Noveanu, M., Breidthardt, T., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.01.076 · Cited by 434 · see citing works
Self-citationScience review: Vasopressin and the cardiovascular system part 1--receptor physiology.
(2003) · Critical Care · doi:10.1186/cc2337 · Cited by 356 · see citing works
Ohlson, L.-O., Larsson, B., Bj�rntorp, P., Eriksson, H., Sv�rdsudd, K., Welin, L., Tibblin, G., & Wilhelmsen, L. (1988) · Diabetologia · doi:10.1007/bf00277480 · Cited by 316 · see citing works
Struck, J., Morgenthaler, N. G., & Bergmann, A. (2005) · Peptides · doi:10.1016/j.peptides.2005.04.019 · Cited by 240 · see citing works
Self-citationVoors, A. A., von Haehling, S., Anker, S. D., Hillege, H. L., Struck, J., Hartmann, O., Bergmann, A., Squire, I., van Veldhuisen, D. J., Dickstein, K., et al. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp098 · Cited by 222 · see citing works
Self-citationCopeptin in the Differential Diagnosis of Hyponatremia
Fenske, W., Störk, S., Blechschmidt, A., Maier, S. G. K., Morgenthaler, N. G., & Allolio, B. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1426 · Cited by 212 · see citing works
Self-citationCloning and characterization of the human V3 pituitary vasopressin receptor
de Keyzer, Y., Auzan, C., Lenne, F., Beldjord, C., Thibonnier, M., Bertagna, X., & Clauser, E. (1994) · FEBS Letters · doi:10.1016/0014-5793(94)01268-7 · Cited by 209 · see citing works
Ginès, P., Wong, F., Watson, H., Milutinovic, S., Ruiz del Arbol, L., & Olteanu, D. (2008) · Hepatology · doi:10.1002/hep.22293 · Cited by 193 · see citing works
Engström, G., Hedblad, B., Nilsson, P. M., Wollmer, P., Berglund, G., & Janzon, L. (2003) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2003.01138.x · Cited by 189 · see citing works
Self-citationRisk Prediction of Cardiovascular Disease in Type 2 Diabetes
Cederholm, J., Eeg-Olofsson, K., Eliasson, B., Zethelius, B., Nilsson, P. M., Gudbjörnsdottir, S., & Register, O. B. O. T. S. N. D. (2008) · Diabetes Care · doi:10.2337/dc08-0662 · Cited by 173 · see citing works
Self-citationSaleem, U., Khaleghi, M., Morgenthaler, N. G., Bergmann, A., Struck, J., Mosley, T. H., & Kullo, I. J. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2278 · Cited by 161 · see citing works
Self-citationPlasma Vasopressin in Uncontrolled Diabetes Mellitus
Zerbe, R. L., Vinicor, F., & Robertson, G. L. (1979) · Diabetes · doi:10.2337/diab.28.5.503 · Cited by 158 · see citing works
Persson, M., Hedblad, B., Nelson, J. J., & Berglund, G. L. (2007) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.107.142679 · Cited by 151 · see citing works
Self-citationTHE EFFECT OF VASOPRESSIN INFUSION ON GLUCOSE METABOLISM IN MAN
SPRUCE, B. A., MCCULLOCH, A. J., BURD, J., ØRSKOV, H., HEATON, A., BAYLIS, P. H., & ALBERTI, K. G. M. M. (1985) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1985.tb00145.x · Cited by 114 · see citing works
Alteration of Glucose Homeostasis in V1a Vasopressin Receptor-Deficient Mice
Aoyagi, T., Birumachi, J.-I., Hiroyama, M., Fujiwara, Y., Sanbe, A., Yamauchi, J., & Tanoue, A. (2007) · Endocrinology · doi:10.1210/en.2006-1315 · Cited by 113 · see citing works
The nature of the hepatic receptors involved in vasopressin-induced glycogenolysis
Keppens, S., & De Wulf, H. (1979) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/0304-4165(79)90371-4 · Cited by 98 · see citing works
Nilsson, P. M., Engström, G., Hedblad, B., et al. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000249638.01416.4b · Cited by 85 · see citing works
Self-citationClassifying diabetes according to the new WHO clinical stages
Lindholm, E., Agardh, E., Tuomi, T., Groop, L., & Agardh, C.-D. (2001) · European Journal of Epidemiology · doi:10.1023/a:1020036805655 · Cited by 82 · see citing works
Self-citationAbu-Basha, E. A., Yibchok-anun, S., & Hsu, W. H. (2002) · Metabolism · doi:10.1053/meta.2002.34052 · Cited by 80 · see citing works
Glucocorticoids Increase Vasopressin V1b Receptor Coupling to Phospholipase C
Rabadan-Diehl, C., & Aguilera, G. (1998) · Endocrinology · doi:10.1210/endo.139.7.6121 · Cited by 78 · see citing works
Mechanism of vasopressin-induced platelet aggregation
Filep, J. G., & Rosenkranz, B. (1987) · Thrombosis Research · doi:10.1016/0049-3848(87)90252-0 · Cited by 76 · see citing works
Insulin hypersensitivity in mice lacking the V1b vasopressin receptor
Fujiwara, Y., Hiroyama, M., Sanbe, A., Aoyagi, T., Birumachi, J., Yamauchi, J., Tsujimoto, G., & Tanoue, A. (2007) · The Journal of Physiology · doi:10.1113/jphysiol.2007.136481 · Cited by 75 · see citing works
Folny, V., Raufaste, D., Lukovic, L., Pouzet, B., Rochard, P., Pascal, M., & Serradeil-Le Gal, C. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00148.2003 · Cited by 61 · see citing works
Management of inherited von Willebrand disease in 2007
Federici, A. B., & Mannucci, P. M. (2007) · Annals of Medicine · doi:10.1080/07853890701513738 · Cited by 53 · see citing works
Human vascular vasopressin receptors: analysis with selective vasopressin receptor antagonists.
Ohlstein, E. H., & Berkowitz, B. A. (1986) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)23348-1 · Cited by 38 · see citing works
Prediction of Incident Diabetes Mellitus in Middle-aged Adults: The Framingham Offspring Study
Wilson, P. W. F. (2007) · Archives of Internal Medicine · doi:10.1001/archinte.167.10.1068 · Cited by 4 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
An obligatory role for neurotensin in high-fat-diet-induced obesity
Li, J., Song, J., Zaytseva, Y. Y., Liu, Y., Rychahou, P. G., Jiang, K., Starr, M. E., Kim, J. T., Harris, J. W., Yiannikouris, F. B., et al. (2016) · Nature · doi:10.1038/nature17662 · Cited by 260 · see citing works
Self-citationWater Intake, Water Balance, and the Elusive Daily Water Requirement
Armstrong, L. E., & Johnson, E. C. (2018) · Nutrients · doi:10.3390/nu10121928 · Cited by 236 · see citing works
Vasopressin: a novel target for the prevention and retardation of kidney disease?
Bankir, L., Bouby, N., & Ritz, E. (2013) · Nature Reviews Nephrology · doi:10.1038/nrneph.2013.22 · Cited by 214 · see citing works
Enhörning, S., Bankir, L., Bouby, N., Struck, J., Hedblad, B., Persson, M., Morgenthaler, N. G., Nilsson, P. M., & Melander, O. (2012) · International Journal of Obesity · doi:10.1038/ijo.2012.88 · Cited by 193 · see citing works
Self-citationPlasma Copeptin, A Unifying Factor behind the Metabolic Syndrome
Enhörning, S., Struck, J., Wirfält, E., Hedblad, B., Morgenthaler, N. G., & Melander, O. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2981 · Cited by 177 · see citing works
Self-citationLow Water Intake and Risk for New-Onset Hyperglycemia
Roussel, R., Fezeu, L., Bouby, N., Balkau, B., Lantieri, O., Alhenc-Gelas, F., Marre, M., Bankir, L., & for the D.E.S.I.R. Study Group (2011) · Diabetes Care · doi:10.2337/dc11-0652 · Cited by 165 · see citing works
“Knowing the rise of vasopressin in diabetes, its effect on glycemia, gluconeogenesis, and glucagon release, it is surprising that no attention had been given to vasopressin as a possible risk factor for hyperglycemia and diabetes until a recent report of an association between copeptin and the incidence of diabetes (1…”
BackgroundPediatric Thermoregulation: Considerations in the Face of Global Climate Change
Smith, C. J. (2019) · Nutrients · doi:10.3390/nu11092010 · Cited by 162 · see citing works
“Evidence does indicate low fluid intake is independently associated with developing hyperglycemia [145], type 2 diabetes mellitus [146], and renal dysfunction including chronic kidney disease (CKD) [144], with inconsistent evidence of cardiovascular disease risk.”
BackgroundMelander, O., Maisel, A. S., Almgren, P., Manjer, J., Belting, M., Hedblad, B., Engström, G., Kilger, U., Nilsson, P. M., Bergmann, A., et al. (2012) · JAMA · doi:10.1001/jama.2012.12998 · Cited by 149 · see citing works
Self-citationMagnusson, M., Jujić, A., Hedblad, B., Engström, G., Persson, M., Struck, J., Morgenthaler, N. G., Nilsson, P. M., Newton‐Cheh, C., Wang, T. J., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2425 · Cited by 149 · see citing works
“For example, in the population-based Malmö Diet and Cancer (MDC) study cardiovascular cohort (MDC-CC), as many as 75% of those with diabetic fasting blood glucose values were unaware that they had diabetes (19).”
MethodSelf-citationCopeptin and its potential role in diagnosis and prognosis of various diseases
Dobsa, L., & Edozien, K. C. (2013) · Biochemia Medica · doi:10.11613/bm.2013.021 · Cited by 149 · see citing works
“tients with heart failure who generally have a lower osmolality (16,31).”
BackgroundMethodInfluentialRed cell distribution width, haemoglobin A 1c and incidence of diabetes mellitus
Engström, G., Smith, J. G., Persson, M., Nilsson, P. M., Melander, O., & Hedblad, B. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12188 · Cited by 134 · see citing works
Self-citationRoussel, R., Fezeu, L., Marre, M., Velho, G., Fumeron, F., Jungers, P., Lantieri, O., Balkau, B., Bouby, N., Bankir, L., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2295 · Cited by 130 · see citing works
Vasopressin and Copeptin in health and disease
Christ‐Crain, M. (2019) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-019-09509-9 · Cited by 128 · see citing works
“Most but not all studies investigating copeptin levels in patients with type 2 diabetes showed a positive association of copeptin with blood glucose [95].”
BackgroundCopeptin (CTproAVP), a new tool for understanding the role of vasopressin in pathophysiology
Bolignano, D., Cabassi, A., Fiaccadori, E., Ghigo, E., Pasquali, R., Peracino, A. P., Peri, A., Plebani, M., Santoro, A., Settanni, F., et al. (2014) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2014-0379 · Cited by 123 · see citing works
High intakes of protein and processed meat associate with increased incidence of type 2 diabetes
Ericson, U., Sonestedt, E., Gullberg, B., Hellstrand, S., Hindy, G., Wirfält, E., & Orho‐Melander, M. (2012) · British Journal Of Nutrition · doi:10.1017/s0007114512003017 · Cited by 116 · see citing works
“HbA1c Register (date information for all the 835 additional cases that were identified by this register and for six of the cases without date information in Diabetes 2000)((23)) and (3) the Swedish National Diabetes Register (date information for U.”
BackgroundSelf-citationProtein- and diabetes-induced glomerular hyperfiltration: role of glucagon, vasopressin, and urea
Bankir, L., Roussel, R., & Bouby, N. (2015) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00614.2014 · Cited by 111 · see citing works
Tada, H., Shiffman, D., Smith, J. G., Sjögren, M., Lubitz, S. A., Ellinor, P. T., Louie, J. Z., Catanese, J. J., Engström, G., Devlin, J. J., et al. (2014) · Stroke · doi:10.1161/strokeaha.114.006072 · Cited by 110 · see citing works
Self-citationAydın, S., Kuloğlu, T., & Aydın, S. (2013) · Peptides · doi:10.1016/j.peptides.2013.07.001 · Cited by 110 · see citing works
A Review of the Nonpressor and Nonantidiuretic Actions of the Hormone Vasopressin
Mavani, G. P., DeVita, M. V., & Michelis, M. F. (2015) · Frontiers in Medicine · doi:10.3389/fmed.2015.00019 · Cited by 105 · see citing works
“In the rat model, chronic infusion of desmopressin (DDAVP) caused an increase in proteinuria and AVP suppression caused a decrease in proteinuria and improvement in renal function (16).”
BackgroundCopeptin is an independent predictor of diabetic heart disease and death
Enhörning, S., Hedblad, B., Nilsson, P. M., Engström, G., & Melander, O. (2014) · American Heart Journal · doi:10.1016/j.ahj.2014.11.020 · Cited by 98 · see citing works
Self-citationHydration for health hypothesis: a narrative review of supporting evidence
Perrier, E. T., Armstrong, L. E., Bottin, J. H., Clark, W. F., Dolci, A., Guelinckx, I., Iroz, A., Kavouras, S. A., Lang, F. J. W., Lieberman, H. R., et al. (2020) · European Journal of Nutrition · doi:10.1007/s00394-020-02296-z · Cited by 98 · see citing works
Self-citationCopeptin predicts coronary artery disease cardiovascular and total mortality
Tasevska, I., Enhörning, S., Persson, M., Nilsson, P. M., & Melander, O. (2015) · Heart · doi:10.1136/heartjnl-2015-308183 · Cited by 97 · see citing works
Self-citationHydration, dehydration, underhydration, optimal hydration: are we barking up the wrong tree?
Kavouras, S. A. (2019) · European Journal of Nutrition · doi:10.1007/s00394-018-01889-z · Cited by 92 · see citing works
New insights into urea and glucose handling by the kidney, and the urine concentrating mechanism
Bankir, L., & Yang, B. (2012) · Kidney International · doi:10.1038/ki.2012.67 · Cited by 88 · see citing works
Copeptin, Insulin Resistance, and Risk of Incident Diabetes in Older Men
Wannamethee, S. G., Welsh, P. I., Papacosta, O., LENNON, L. T., Whincup, P. H., & Sattar, N. A. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2362 · Cited by 89 · see citing works
“The association between copeptin and risk of incident diabetes in the present study was weaker than that observed in the MDC study (14).”
BackgroundResultInfluentialCopeptin and cardiovascular disease: A review of a novel neurohormone
Yalta, K., Yalta, T. D., Sıvrı, N., & Yetkın, E. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.12.039 · Cited by 89 · see citing works
“Copeptin in cardiometabolic disease [77–80] - May serve as a promising marker of cardiometabolic disease including DM, MetS (beyond”
BackgroundMethodInfluentialRole of TCF7L2 risk variant and dietary fibre intake on incident type 2 diabetes
Hindy, G., Sonestedt, E., Ericson, U., Jing, X., Zhou, Y., Hansson, O., Renström, E., Wirfält, E., & Orho‐Melander, M. (2012) · Diabetologia · doi:10.1007/s00125-012-2634-x · Cited by 91 · see citing works
“To identify cases that were not diagnosed at the hospital, we used the local HbA1c register, which contains data from institutional and non-institutional care in Malmö since 1988 [19].”
MethodSelf-citationTentzeris, I., Járai, R., Farhan, S., Perkmann, T., Schwarz, M. A., Jakl, G., Wojta, J., & Huber, K. (2011) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfr049 · Cited by 89 · see citing works
“Copeptin has been shown to be elevated in haemorrhagic and septic shock,(19) acute ischaemic stroke,(20) and intracerebral bleeding,(21) as well as in patients with diabetes mellitus.(22) Copeptin levels were significantly higher in patients with a history of diabetes mellitus and significantly increased with higher N…”
BackgroundMetabolic and Kidney Diseases in the Setting of Climate Change, Water Shortage, and Survival Factors
Johnson, R. J., Stenvinkel, P., Jensen, T., Lanaspa, M. A., Roncal, C., Song, Z., Bankir, L., & Sánchez‐Lozada, L. G. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015121314 · Cited by 84 · see citing works
Boertien, W. E., Riphagen, I. J., Drion, I., Alkhalaf, A., Bakker, S. J. L., Groenier, K. H., Struck, J., de Jong, P. E., Bilo, H. J. G., Kleefstra, N., et al. (2013) · Diabetologia · doi:10.1007/s00125-013-2922-0 · Cited by 86 · see citing works
“From the literature it is known that copeptin is associated with incident microalbuminuria in a general population cohort [23, 24] and with incident diabetes in the general population [11, 12].”
BackgroundSelf-citationTaveau, C., Chollet, C., Waeckel, L., Desposito, D., Bichet, D. G., Arthus, M.-F., Magnan, C., Philippe, E., Paradis, V., Foufelle, F., et al. (2015) · Diabetologia · doi:10.1007/s00125-015-3496-9 · Cited by 86 · see citing works
Self-citationAbbasi, A., Corpeleijn, E., Meijer, E., Postmus, D., Gansevoort, R. T., Gans, R. O. B., Struck, J., Hillege, H. L., Stolk, R. P., Navis, G., et al. (2012) · Diabetologia · doi:10.1007/s00125-012-2545-x · Cited by 85 · see citing works
“One recent study found that high baseline levels of copeptin are associated with increased risk for development of type 2 diabetes [6].”
BackgroundMethodResultInfluentialSelf-citationDimethylglycine Deficiency and the Development of Diabetes
Magnusson, M., Wang, T. J., Clish, C. B., Engström, G., Nilsson, P. M., Gerszten, R. E., & Melander, O. (2015) · Diabetes · doi:10.2337/db14-1863 · Cited by 74 · see citing works
“Incident diabetes (occurring after the MDC and MPP baseline examinations) was retrieved through record linkage of the Swedish personal identification number with national and regional registers as follows: the Malmö HbA1c register that analyzed all HbA1c samples at the Department of Clinical Chemistry obtained in inst…”
MethodSelf-citationHorsch, A., Kang, J. S., Vial, Y., Ehlert, U., Borghini, A., Marques-Vidal, P. M., Jacobs, I., & Puder, J. J. (2016) · British Journal of Health Psychology · doi:10.1111/bjhp.12197 · Cited by 72 · see citing works
Stookey, J. D., Kavouras, S. A., Suh, H., & Lang, F. J. W. (2020) · Nutrients · doi:10.3390/nu12040905 · Cited by 76 · see citing works
“Vasopressin-mediated pathways are associated with increased chronic disease mortality [19,34,37].”
BackgroundPlasma Copeptin, AVP Gene Variants, and Incidence of Type 2 Diabetes in a Cohort From the Community
Roussel, R., Boustany, R. E., Bouby, N., Potier, L., Fumeron, F., Mohammedi, K., Balkau, B., Tichet, J., Bankir, L., Marre, M., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1113 · Cited by 70 · see citing works
“Other investigations have shown circulating copeptin to be positively correlated with insulin resistance and/or with the metabolic syndrome in African-American (21), non-Hispanic White American (21), and North European cohorts (35, 38), and with the incidence or the prevalence of T2DM in North European cohorts (22, 24…”
BackgroundDistinguishing Low and High Water Consumers—A Paradigm of Disease Risk
Armstrong, L. E., Muñoz, C. X., & Armstrong, E. G. (2020) · Nutrients · doi:10.3390/nu12030858 · Cited by 71 · see citing works
Cadmium Exposure and Incidence of Diabetes Mellitus - Results from the Malmö Diet and Cancer Study
Borné, Y., Fagerberg, B., Persson, M., Sällsten, G., Forsgard, N., Hedblad, B., Barregård, L., & Engström, G. (2014) · PLoS ONE · doi:10.1371/journal.pone.0112277 · Cited by 68 · see citing works
“…incident diabetes was identified in the Malmo¨ HbA1c register (MHR), the Swedish National Diabetes Register (NDR), the Swedish inpatient register, the Swedish outpatient register, the nationwide Swedish drug prescription register and the regional Diabetes 2000 register of the Ska˚ne region [28,29].”
Self-citationArginine vasopressin: Direct and indirect action on metabolism
Yoshimura, M., Conway-Campbell, B. L., & Ueta, Y. (2021) · Peptides · doi:10.1016/j.peptides.2021.170555 · Cited by 64 · see citing works
Dmitrieva, N. I., Gagarin, A., Liu, D., Wu, C. O., & Boehm, M. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2022.104404 · Cited by 70 · see citing works
Enhörning, S., Tasevska, I., Roussel, R., Bouby, N., Persson, M., Burri, P., Bankir, L., & Melander, O. (2017) · European Journal of Nutrition · doi:10.1007/s00394-017-1595-8 · Cited by 67 · see citing works
“Furthermore, we showed that subjects with high copeptin concentration have an increased risk of all components of the metabolic syndrome [11, 14, 15] as well as cardiovascular disease and premature mortality, both in diabetics and non-diabetics [16–18].”
BackgroundMethodResultInfluentialSelf-citationTasevska, I., Enhörning, S., Christensson, A. G., Persson, M., Nilsson, P. M., & Melander, O. (2016) · American Journal of Nephrology · doi:10.1159/000447522 · Cited by 65 · see citing works
Self-citationIncreased Levels of Copeptin Before Clinical Diagnosis of Preeclampsia
Yeung, E. H., Liu, A., Mills, J. L., Zhang, C., Männistö, T. I., Lu, Z., Tsai, M. Y., & Mendola, P. (2014) · Hypertension · doi:10.1161/hypertensionaha.114.03762 · Cited by 65 · see citing works
“Epidemiological evidence have observed associations between elevated copeptin levels and increased risk of incident type 2 diabetes mellitus.(16,34) Despite these findings, our study showed no association between copeptin and risk of GDM.”
BackgroundRydberg, M., Zimmerman, M., Gottsäter, A., Nilsson, P. M., Melander, O., & Dahlin, L. B. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001298 · Cited by 65 · see citing works
Self-citationEffect of increased water intake on plasma copeptin in healthy adults
Lemetais, G., Melander, O., Vecchio, M., Bottin, J. H., Enhörning, S., & Perrier, E. T. (2017) · European Journal of Nutrition · doi:10.1007/s00394-017-1471-6 · Cited by 64 · see citing works
“In an analysis conducted on a subset of participants in the Malmö diet and cancer study, higher baseline plasma copeptin was associated with increased prevalence of type 2 diabetes mellitus [2].”
MethodSelf-citationEnhörning, S., Brunkwall, L., Tasevska, I., Ericson, U., Tholin, J. P., Persson, M., Lemetais, G., Vanhaecke, T., Dolci, A., Perrier, E. T., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-02195 · Cited by 64 · see citing works
“Individuals aged 20 to 75 years and had high plasma copeptin concentrations [>6.1 pmol · L in women and >10.7 pmol · L in men, corresponding to the top quartile of copeptin in the Malmö Diet and Cancer–Cardiovascular Cohort (6)] were deemed eligible for the current study and contacted by letter and telephone (Fig.”
BackgroundResultInfluentialSelf-citationCarlsson, S., Andersson, T., Araghi, M., Galanti, R., Lager, A., Lundberg, M., Nilsson, P., Norberg, M., Pedersen, N. L., Trolle‐Lagerros, Y., et al. (2017) · Journal of Internal Medicine · doi:10.1111/joim.12592 · Cited by 56 · see citing works
Self-citationVasopressin and metabolic disorders: translation from experimental models to clinical use
Nakamura, K., Velho, G., & Bouby, N. (2017) · Journal of Internal Medicine · doi:10.1111/joim.12649 · Cited by 59 · see citing works
Reduced water intake deteriorates glucose regulation in patients with type 2 diabetes
Johnson, E. C., Bardis, C. N., Jansen, L. T., Adams, J. D., Kirkland, T. W., & Kavouras, S. A. (2017) · Nutrition Research · doi:10.1016/j.nutres.2017.05.004 · Cited by 65 · see citing works
Velho, G., Boustany, R. E., Lefèvre, G., Mohammedi, K., Fumeron, F., Potier, L., Bankir, L., Bouby, N., Hadjadj, S., Marre, M., et al. (2016) · Diabetes Care · doi:10.2337/dc16-1003 · Cited by 60 · see citing works
Genetic vasopressin 1b receptor variance in overweight and diabetes mellitus
Enhörning, S., Sjögren, M., Hedblad, B., Nilsson, P. M., Struck, J., & Melander, O. (2016) · European Journal of Endocrinology · doi:10.1530/eje-15-0781 · Cited by 58 · see citing works
Self-citationVasopressin, from Regulator to Disease Predictor for Diabetes and Cardiometabolic Risk
Melander, O. (2016) · Annals of Nutrition and Metabolism · doi:10.1159/000446201 · Cited by 51 · see citing works
Self-citationVasopressin mediates fructose-induced metabolic syndrome by activating the V1b receptor
Andrés-Hernando, A., Jensen, T., Kuwabara, M., Orlicky, D. J., Cicerchi, C., Li, N., Roncal-Jiménez, C. A., García, G., Ishimoto, T., MacLean, P. S., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.140848 · Cited by 56 · see citing works
“Elevated copeptin can also increase the risk of obesity and diabetes (17, 21).”
Thirst and Drinking Paradigms: Evolution from Single Factor Effects to Brainwide Dynamic Networks
Armstrong, L. E., & Kavouras, S. A. (2019) · Nutrients · doi:10.3390/nu11122864 · Cited by 57 · see citing works
Velho, G., Ragot, S., Boustany, R. E., Saulnier, P., Fraty, M., Mohammedi, K., Fumeron, F., Potier, L., Marre, M., Hadjadj, S., et al. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0753-5 · Cited by 53 · see citing works
Sonestedt, E., Lyssenko, V., Ericson, U., Gullberg, B., Wirfält, E., Groop, L., & Orho‐Melander, M. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2444 · Cited by 55 · see citing works
“Type 2 diabetes cases were identified by three registers: the Swedish National Diabetes Register (18), the regional Diabetes 2000 register of the Skåne region (19), and the local HbA1c register (20).”
BackgroundSelf-citationApproach to the Patient: “Utility of the Copeptin Assay”
Christ‐Crain, M., Refardt, J. C., & Winzeler, B. F. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac070 · Cited by 55 · see citing works
Risk stratification of normotensive pulmonary embolism: prognostic impact of copeptin
Hellenkamp, K., Schwung, J., Rossmann, H., et al. (2015) · European Respiratory Journal · doi:10.1183/13993003.00857-2015 · Cited by 53 · see citing works
von Haehling, S., Papassotiriou, J., Morgenthaler, N. G., Hartmann, O., Doehner, W., Stellos, K., Wurster, T. H., Schuster, A., Nagel, E. C., Gawaz, M., et al. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2011.12.105 · Cited by 53 · see citing works
“Other clinical entities associated with elevated levels of copeptin include pulmonary disorders and cardiovascular diseases as well as insulin resistance and metabolic syndrome [14,38–40].”
BackgroundSelf-citationLong-term health outcomes associated with hydration status
Dmitrieva, N. I., Boehm, M., Yancey, P. H., & Enhörning, S. (2024) · Nature Reviews Nephrology · doi:10.1038/s41581-024-00817-1 · Cited by 60 · see citing works
Self-citationShifting Focus: From Hydration for Performance to Hydration for Health
Perrier, E. T. (2017) · Annals of Nutrition and Metabolism · doi:10.1159/000462996 · Cited by 52 · see citing works
Carroll, H. A., Davis, M. G., & Papadaki, A. (2015) · Nutrition Research · doi:10.1016/j.nutres.2015.06.015 · Cited by 49 · see citing works
“Although this anti-diuretic hormone is traditionally associated with blood pressure regulation, it has also been shown to affect glucose homeostasis and insulin resistance [24-26].”
BackgroundLauber, C., Gerl, M. J., Klose, C. D., Ottosson, F. A., Melander, O., & Simons, K. (2022) · PLoS Biology · doi:10.1371/journal.pbio.3001561 · Cited by 49 · see citing works
“0% in the US National Glyco hemoglobin 5 Standardization Program (NGSP), in the Malmö HbA1c register [45].”
BackgroundSelf-citationGLUT4 Storage Vesicles: Specialized Organelles for Regulated Trafficking.
Li, D. T., Habtemichael, E. N., Julca-Zevallos, O., Sales, C., Westergaard, X. O., DeVries, S. G., Ruiz, D. M., Sayal, B. S., & Bogan, J. S. (2019) · Europe PMC (PubMed Central) · Cited by 46 · see citing works
Pikkemaat, M., Melander, O., & Boström, K. B. (2015) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2015.07.006 · Cited by 45 · see citing works
Self-citationMolvin, J., Pareek, M., Jujić, A., et al. (2019) · Scientific Reports · doi:10.1038/s41598-018-36512-y · Cited by 43 · see citing works
Self-citationErrors in Dual Energy X-Ray Absorptiometry Estimation of Body Composition Induced by Hypohydration
Rodríguez-Sánchez, N., & Galloway, S. D. R. (2014) · International Journal of Sport Nutrition and Exercise Metabolism · doi:10.1123/ijsnem.2014-0067 · Cited by 43 · see citing works
Peptides in the regulation of glucagon secretion
Andersen, D. B., & Holst, J. J. (2021) · Peptides · doi:10.1016/j.peptides.2021.170683 · Cited by 46 · see citing works
“different AVP receptor sub-types; V2R in the renal collecting ducts [282], V1aR located in the liver and vasculature [283,284], V1bR in the”
Patsouras, A., Farmaki, P., Garmpi, A., Damaskos, C., Garmpis, N., Mantas, D., & Diamantis, E. (2019) · In Vivo · doi:10.21873/invivo.11572 · Cited by 41 · see citing works
Copeptin: Pathophysiology and potential clinical impact
Łukaszyk, E., & Małyszko, J. (2015) · Advances in Medical Sciences · doi:10.1016/j.advms.2015.07.002 · Cited by 44 · see citing works
Enhörning, S., & Melander, O. (2018) · Annals of Nutrition and Metabolism · doi:10.1159/000488304 · Cited by 38 · see citing works
Self-citationCopeptin in obese children and adolescents: relationships to body mass index, cortisol and gender
Rothermel, J., Kulle, A. E., Holterhus, P., Toschke, C., Lass, N., & Reinehr, T. (2016) · Clinical Endocrinology · doi:10.1111/cen.13235 · Cited by 41 · see citing works
Genetics of Type 2 Diabetes: It Matters From Which Parent We Inherit the Risk
Lyssenko, V., Groop, L., & Prasad, R. B. (2015) · The Review of Diabetic Studies · doi:10.1900/rds.2015.12.233 · Cited by 40 · see citing works
Self-citationSontrop, J. M., Huang, S.-H., Garg, A. X., MOIST, L. M., House, A. A., Gallo, K., & Clark, W. F. (2015) · BMJ Open · doi:10.1136/bmjopen-2015-008634 · Cited by 39 · see citing works
“50 Copeptin is also inversely related to eGFR, is positively associated with urine protein, and is a prognostic biomarker for future events of diabetes and heart disease.(6) 8–11 27 28 51 Does it follow that hydration is a unifying factor linking copeptin to kidney function and other diseases, as some suggest?(52) Pos…”
BackgroundCopeptin as a Predictive Marker of Incident Heart Failure
Schill, F., Timpka, S., Nilsson, P. M., et al. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13439 · Cited by 38 · see citing works
“Previous studies have shown a clear predictive role of copeptin in diabetes and diabetic heart disease.(12,13) A substantial number of patients had prevalent diabetes at start”
BackgroundMethodResultSelf-citationEffect of liraglutide on atrial natriuretic peptide, adrenomedullin, and copeptin in PCOS
Frøssing, S., Nylander, M., Kistorp, C., Skouby, S. O., & Faber, J. (2018) · Endocrine Connections · doi:10.1530/ec-17-0327 · Cited by 38 · see citing works
Lang, F. J. W., Guelinckx, I., Lemetais, G., & Melander, O. (2017) · Kidney & Blood Pressure Research · doi:10.1159/000479640 · Cited by 37 · see citing works
Self-citationAcute-phase proteins and incidence of diabetes: a population-based cohort study
Muhammad, I. F., Borné, Y., Hedblad, B., Nilsson, P. M., Persson, M., & Engström, G. (2016) · Acta Diabetologica · doi:10.1007/s00592-016-0903-8 · Cited by 39 · see citing works
“To summarize, incident diabetes was identified by using the Malmö HbA1c register (MHR), the Swedish National Diabetes Register (NDR), the Swedish inpatient register, the Swedish outpatient register, the nationwide Swedish drug prescription register, and the regional Diabetes 2000 register of the Skåne region [20, 21].”
BackgroundMethodSelf-citationMeijer, E., Boertien, W. E., Zietse, R., & Gansevoort, R. T. (2011) · Kidney & Blood Pressure Research · doi:10.1159/000326902 · Cited by 38 · see citing works
“Furthermore, this study showed that copeptin concentration was positively associated with the amount of urinary albumin excretion (fig. 2 a), even after adjustment for potential confounders. The association between albuminuria and copeptin was as strong as the association between albuminuria and known risk factors for…”
BackgroundAcute and chronic hyperglycemic effects of vasopressin in normal rats: involvement of V1Areceptors
Taveau, C., Chollet, C., Bichet, D. G., Velho, G., Guillon, G., Corbani, M., Roussel, R., Bankir, L., Melander, O., & Bouby, N. (2016) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00269.2016 · Cited by 36 · see citing works
“It has been shown that plasma copeptin, a validated surrogate marker for AVP derived from the same preprohormone (30, 45), is associated with insulin resistance, metabolic syndrome, and obesity, and that high-plasma copeptin predicts future diabetes mellitus, independently of known risk factors (10, 13, 15, 43, 44, 46…”
BackgroundSelf-citationAcute effects of salt on blood pressure are mediated by serum osmolality
Kanbay, M., Aslan, G., Afşar, B., Dağel, T., Siriopol, D. C., Kuwabara, M., İncir, S., Çamkıran, V., Rodríguez‐Iturbe, B., Lanaspa, M. A., et al. (2018) · Journal of Clinical Hypertension · doi:10.1111/jch.13374 · Cited by 37 · see citing works
Plasma copeptin as a predictor of kidney disease
Enhörning, S., Christensson, A. G., & Melander, O. (2018) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfy017 · Cited by 37 · see citing works
“As we previously found links between elevated copeptin and incident diabetes and hypertension [5, 7], we suspected that part of the association between elevated copeptin and CKD during follow-up would be driven by new-onset metabolic disease.”
BackgroundSelf-citationTaskin, M. I., Bulbul, E., Adali, E., Hismiogulları, A. A., & Inceboz, U. (2015) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2015.03.006 · Cited by 36 · see citing works
“There are recent studies that associate diabetes mellitus, cardiovascular risk, central obesity, and copeptin levels [12–14].”
BackgroundTap Water Consumption and Perceptions in United States Latinx Adults
Colburn, A. T., & Kavouras, S. A. (2021) · Nutrients · doi:10.3390/nu13092999 · Cited by 35 · see citing works
Jalleh, R. J., & Torpy, D. J. (2021) · Clinical Biochemist Reviews · doi:10.33176/aacb-20-00001 · Cited by 36 · see citing works
Karbek, B., Ozbek, M., Karakose, M., Topaloglu, O., Bozkurt, N., Cakır, E., Aslan, M., & Delibasi, T. (2014) · Journal of Ovarian Research · doi:10.1186/1757-2215-7-31 · Cited by 35 · see citing works
“001) in a large population of 4742 subjects (cross-sectionally) [30].”
BackgroundMethodEricson, U., Rukh, G., Stojkovic, I., Sonestedt, E., Gullberg, B., Wirfält, E., Wallström, P., & Orho‐Melander, M. (2012) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.112.046474 · Cited by 35 · see citing works
“We used information on the date of diagnosis from the registries, which was prioritized in the following order: 1) the regional Diabetes 2000 Registry of Scania (33%) (17), 2) the Malmö Hemoglobin A1c Registry (49%) (18), and 3) the Swedish National Diabetes Registry (18%) (19).”
MethodSelf-citationProcalcitonin and Midregional Proatrial Natriuretic Peptide as Markers of Ischemic Stroke
Mira, K., Moon, Y. P., Paik, M. C., Müeller, B., Huber, A., Sacco, R. L., & Elkind, M. S. V. (2016) · Stroke · doi:10.1161/strokeaha.115.011392 · Cited by 34 · see citing works
“In a subcohort of the Malmö Diet and Cancer study, quartiles of copeptin had dose–response relationships with the odds of developing diabetes mellitus, even after additionally adjusting for baseline fasting glucose and insulin.(4) There is, however, less data available on the role of copeptin as prognostic marker for…”
Svensson, A. K., Svensson, T., Kitliński, M., Almgren, P., Engström, G., Nilsson, P. M., & Melander, O. (2017) · Diabetologia · doi:10.1007/s00125-017-4464-3 · Cited by 31 · see citing works
“The process of endpoint retrieval has been described in detail elsewhere [24].”
Self-citationFluid Intake and Vasopressin: Connecting the Dots
Guelinckx, I., Vecchio, M., Perrier, E. T., & Lemetais, G. (2016) · Annals of Nutrition and Metabolism · doi:10.1159/000446198 · Cited by 30 · see citing works
Then, C., Kowall, B., Lechner, A., Meisinger, C., Heier, M., Köenig, W., Peters, A., Rathmann, W., & Seißler, J. (2014) · Acta Diabetologica · doi:10.1007/s00592-014-0609-8 · Cited by 32 · see citing works
“This may be explained by the application of a novel-automated assay format as compared to the standard chemiluminescence test from the same manufacturer used in previous studies [5–9], but might also be due to different baseline characteristics of the study participants (as discussed below).”
BackgroundMethodResultInfluentialNoor, T., Hanif, F. M., Kiran, Z., Rehman, R., Khan, M. T., Haque, Z., & Nankani, K. (2020) · Archives of Medical Research · doi:10.1016/j.arcmed.2020.05.018 · Cited by 31 · see citing works
Proneurotensin Predicts Cardiovascular Disease in an Elderly Population
Fawad, A., Bergmann, A., Struck, J., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-02424 · Cited by 28 · see citing works
Self-citationCystatin C Is Not Causally Related to Coronary Artery Disease
Färbom, P., Almgren, P., Hedblad, B., Engström, G., Persson, M., Christensson, A. G., & Melander, O. (2015) · PLoS ONE · doi:10.1371/journal.pone.0129269 · Cited by 31 · see citing works
“0 mmol/L), a self-reported physician diagnosis of diabetes, use of anti-diabetic medication or having been diagnosed in local or national Swedish diabetes registries, as described previously [32].”
Self-citationJárai, R., Mahla, E., Perkmann, T., et al. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.06.024 · Cited by 31 · see citing works
Copeptin in fluid disorders and stress
Mu, D., Ma, C., Cheng, J. H., Zou, Y., Qiu, L., & Cheng, X. (2022) · Clinica Chimica Acta · doi:10.1016/j.cca.2022.02.002 · Cited by 28 · see citing works
Pathophysiology and Prevention of Heart Disease in Diabetes Mellitus
Oktay, A. A., Aktürk, H. K., Esenboğa, K., Javed, F., Polin, N. M., & Jahangir, E. (2017) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2017.05.001 · Cited by 32 · see citing works
Zellweger, C., Wildi, K. S., Twerenbold, R., Reichlin, T., Naduvilekoot, A., Neuhaus, J. D., Balmelli, C., Gabutti, M., Afify, A. A., Ballarino, P., et al. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.04.134 · Cited by 27 · see citing works
“Copeptin seems to have a special role in diabetic patients: recently published data [13,14] showed an increased risk for DM in patients with elevated copeptin levels.”
BackgroundResultBorné, Y., Nilsson, P. M., Melander, O., Hedblad, B., & Engström, G. (2015) · European Journal of Public Health · doi:10.1093/eurpub/ckv044 · Cited by 28 · see citing works
Self-citationAsferg, C. L., Andersen, U. B., Linneberg, A., Goetze, J. P., & Jeppesen, J. L. (2014) · Diabetic Medicine · doi:10.1111/dme.12411 · Cited by 26 · see citing works
- Authors
- Enhörning, S., Wang, T. J., Nilsson, P. M., Almgren, P., Hedblad, B., Berglund, G., Struck, J., Morgenthaler, N. G., Bergmann, A., Lindholm, E., Groop, L., Lyssenko, V., Orho-Melander, M., Newton-Cheh, C., & Melander, O.
- Affiliations
- From the Department of Clinical Sciences, Lund University (S.E., P.M.N., P.A., B.H., G.B., E.L., L.G., V.L., M.O.M., O.M.), and Department of Internal Medicine (S.E., P.M.N., O.M.), Malmö University Hospital, Malmö, Sweden; Cardiology Division (T.J.W., C.N.-C.), Center for Human Genetic Research (C.N.-C.), and Cardiovascular Research Center (T.J.W., C.N.-C.), Massachusetts General Hospital, Harvard Medical School, Boston; Program in Medical and Population Genetics, Broad Institute of Harvard and...
- Broad Institute (US)
- ORCID
- Venue
- Circulation
- Published
- 2010-05-18
- Volume
- 121
- Issue
- 19
- Pages
- 2102-2108
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- PMC
- PMC3763235
- OpenAlex
- W1963947490
- Cited by
- 299
- References
- 37
- Citations by year
- 2026: 7 · 2025: 9 · 2024: 19 · 2023: 11 · 2022: 12 · 2021: 23 · 2020: 27 · 2019: 27 · 2018: 20 · 2017: 18 · 2016: 32 · 2015: 31 · 2014: 17 · 2013: 20 · 2012: 15
- FWCI
- 12.23
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Circulation (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Funders
- National Heart, Lung, and Blood Institute (R01HL086875, R01HL083197, R01HL098283, K23HL080025)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK081572)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Electrolyte and hormonal disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Epidemiology › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- copeptin, diabetes mellitus, vasopressin, insulin resistance, incident diabetes risk, glucose metabolism, fasting insulin, fasting blood glucose, biomarkers of diabetes risk
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Type 2, Female, Follow-Up Studies, Glycopeptides, Humans, Insulin, Insulin Resistance, Male, Middle Aged, Predictive Value of Tests, Risk Factors, Sweden, Prevalence, Multivariate Analysis, Logistic Models
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Claims read under definition version 3 (extract-v3) on 2026-09-28.
Classified by jev-1.13-20260917 (gold-guideline-v0.2) on 2026-09-28.
Cited sources are checked by gpt-6-sol.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
